Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study

An overview of thrombotic complications of old and new anticancer drugs

(2020) Marcel Levi et al.   THROMBOSIS RESEARCH

Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy

(2020) Florian Moik et al.   BLOOD

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

(2019) Alok A. Khorana et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

(2019) Yucai Wang et al.   JAMA Oncology

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients

(2019) Federico Nichetti et al.   Cancers

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

(2018) Marina Chiara Garassino et al.   LANCET ONCOLOGY

Immune checkpoint inhibitors and cardiovascular toxicity

(2018) Alexander R Lyon et al.   LANCET ONCOLOGY

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

(2018) Marc Carrier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer

(2017) H.E. Fuentes et al.   THROMBOSIS RESEARCH

Venous Thromboembolism in Patients Diagnosed With Lung Cancer

(2016) E. Salla et al.   ANGIOLOGY

Cross Talk Pathways Between Coagulation and Inflammation

(2016) Jonathan H. Foley et al.   CIRCULATION RESEARCH

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venous thromboembolism and lung cancer: a review

(2015) Carolina Vitale et al.   MULTIDISCIPLINARY RESPIRATORY MEDICINE

Prevalence and Associations of VTE in Patients With Newly Diagnosed Lung Cancer

(2014) Yuhui Zhang et al.   CHEST

30-Year Mortality After Venous Thromboembolism

(2014) Kirstine Kobberøe Søgaard et al.   CIRCULATION

Programmed Cell Death-1 Deficiency Exacerbates T Cell Activation and Atherogenesis despite Expansion of Regulatory T Cells in Atherosclerosis-Prone Mice

(2014) Clément Cochain et al.   PLoS One

Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials

(2012) F. Petrelli et al.   ANNALS OF ONCOLOGY

A Systematic Review of Pulmonary Embolism in Patients With Lung Cancer

(2012) Rafael D. Malgor et al.   ANNALS OF THORACIC SURGERY

Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis

(2012) Sonia Seng et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer

(2012) G.C. Connolly et al.   LUNG CANCER

Impairment of the Programmed Cell Death-1 Pathway Increases Atherosclerotic Lesion Development and Inflammation

(2011) De-xiu Bu et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis

(2011) Russell A. Moore et al.   JOURNAL OF CLINICAL ONCOLOGY

Lung cancer associated venous thromboembolic disease: A comprehensive review

(2011) Luis Corrales-Rodriguez et al.   LUNG CANCER

Prediction of venous thromboembolism in cancer patients

(2010) C. Ay et al.   BLOOD

Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials

(2010) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

(2010) Lucio Crinò et al.   LANCET ONCOLOGY

Venous thromboembolism and prognosis in cancer

(2010) Alok A. Khorana   THROMBOSIS RESEARCH

Clinical Predictors for Fatal Pulmonary Embolism in 15 520 Patients With Venous Thromboembolism

(2008) Silvy Laporte et al.   CIRCULATION

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients

(2008) Shobha Rani Nalluri et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

(2008) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY